Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

TScan Therapeutics (TCRX) Return on Equity (2021 - 2025)

TScan Therapeutics (TCRX) has disclosed Return on Equity for 5 consecutive years, with 0.97% as the latest value for Q4 2025.

  • Quarterly Return on Equity fell 43.0% to 0.97% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.97% through Dec 2025, down 43.0% year-over-year, with the annual reading at 0.71% for FY2025, 7.0% down from the prior year.
  • Return on Equity for Q4 2025 was 0.97% at TScan Therapeutics, down from 0.88% in the prior quarter.
  • The five-year high for Return on Equity was 0.62% in Q1 2021, with the low at 0.97% in Q4 2025.
  • Average Return on Equity over 5 years is 0.48%, with a median of 0.56% recorded in 2023.
  • Peak annual rise in Return on Equity hit 24bps in 2022, while the deepest fall reached -105bps in 2022.
  • Over 5 years, Return on Equity stood at 0.29% in 2021, then plummeted by -111bps to 0.61% in 2022, then grew by 9bps to 0.56% in 2023, then increased by 4bps to 0.54% in 2024, then crashed by -81bps to 0.97% in 2025.
  • According to Business Quant data, Return on Equity over the past three periods came in at 0.97%, 0.88%, and 0.7% for Q4 2025, Q3 2025, and Q2 2025 respectively.